Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.
Steven I. Sherman, MD, from the MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine resistance for patients with thyroid cancer.
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, defines a "smart" cancer.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses maintenance therapy for patients with breast cancer.
Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.
Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an overview of the IMPAKT conference.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
Laura Esserman, MD, MBA, Professor, University of California, San Francisco, comments on the findings from the I-SPY 1 trial and the basis for the I-SPY 2 trial in patients with breast cancer.
Joan Such Lockhart, PhD, RN, AOCN, FAAN, from the Duquesne University School of Nursing, discusses resources currently available to help strengthen the oncology training of nurses.
Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, comments on the diagnosis and testing of a patient with chronic myeloid leukemia (CML).
Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes a phase I/II study examining the safety and efficacy of orteronel in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.
Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the diagnosis of patients with follicular lymphoma.
E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the lasting issues in the treatment of breast cancer.
Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms.
Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, discusses the need for a team environment when treating an older patient.
Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma.
Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia.
Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma.
José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.
Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.
Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).